University of Eastern Finland: Cholesterol-lowering Drug Evolocumab Significantly Reduces the Risk of a First Cardiovascular
November 26, 2025
November 26, 2025
KUOPIO, Finland, Nov. 26 (TNSjou) -- The University of Eastern Finland issued the following news:
* * *
Cholesterol-lowering drug evolocumab significantly reduces the risk of a first cardiovascular
In a large international trial, the PCSK9 inhibitor evolocumab reduced the risk of a first cardiovascular event among high-risk patients without a previous myocardial infarction or stroke.
In Finland, the study was led by Professor Johanna Kuusisto a . . .
* * *
Cholesterol-lowering drug evolocumab significantly reduces the risk of a first cardiovascular
In a large international trial, the PCSK9 inhibitor evolocumab reduced the risk of a first cardiovascular event among high-risk patients without a previous myocardial infarction or stroke.
In Finland, the study was led by Professor Johanna Kuusisto a . . .